# Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

> **NCT05897541** · PHASE3 · COMPLETED · sponsor: **Shionogi** · enrollment: 2387 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DRUG:** S-217622
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05897541
- **Lead sponsor:** Shionogi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-09
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-09-18
- **Target enrollment:** 2387 (ACTUAL)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05897541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05897541, "Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05897541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*